Form 4: Bioxytran Director Alan Hoberman Acquires Shares

Bioxytran director Alan Hoberman acquired 97,535 preferred shares at $0.315 per share on January 6, 2025.

Summary

• Alan Hoberman, a director at Bioxytran, Inc., acquired 97,535 preferred shares on January 6, 2025.
• The shares were purchased at a price of $0.315 each.
• Following the transaction, Mr. Hoberman's total holdings increased to 367,202 preferred shares.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a share purchase by a director. It is neither overwhelmingly positive nor negative, but insider buying is generally viewed as a positive sign.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who trade shares in their own company. It provides transparency into insider transactions.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is typical for directors and officers who are required to disclose their trades in company stock.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Bioxytran, BIXT, Alan Hoberman, share acquisition, preferred shares, director, insider trading